. EGF-induced inhibition of glucose transport is mediated by PKC and MAPK signal pathways in primary cultured chicken hepatocytes.
GLUCOSE is a major fuel for energy metabolism in hepatocytes and is transported into hepatocytes via glucose transporters (GLUTs). Facilitative GLUT2 is the major subtype that is expressed in hepatocytes (6, 20, 26, 51) . Altered transport of glucose into hepatocytes may be another factor that might help understanding the physiological action of EGF. In chickens and mammals, D-glucose uses the GLUT2 mechanism to cross the basolateral membrane (9) . EGF is a potent mitogen that has been shown to promote DNA synthesis and transcription of RNA leading to protein synthesis (9, 18) . EGF has also been shown to regulate several transporters such as GLUTs and glycylsarcosine transporters (19, 29) . EGF is a key regulatory polypeptide in the function of hepatocytes that are rich in EGF receptors (EGFRs) (21, 23, 24, 43) .
EGF exerts its actions by binding to its receptor with a tyrosine kinase residue (14) . The activation of the EGFR may trigger the phosphatidylinositol pathway such as through the activation of PKC and inositol (1, 4, 5) -trisphosphate [Ins(1,4,5)P 3 ] as well as by increasing the intracellular cytoplasmic calcium concentration. It is well known that MAPKs are activated in response to external stimuli in many cell types and play a key role in many signal transduction pathways. ERKs are activated by the phosphorylation of threonine and tyrosine residues (34) . In addition, several reports have suggested that other MAPK cascades also drive specific cell responses to extracellular stimuli, including p38 and JNK, which can affect the function of hepatocytes (31, 50) . These reports also suggested that EGF stimulates MAPK cascades in chicken hepatocytes. Recent reports have demonstrated that EGF activates p44/42 MAPK, p38 MAPK, or JNK/stress-activated protein kinase (SAPK) kinase in hepatocytes. However, the involvement of MAPKs in the EGF-induced alteration of GLUTs in chicken hepatocytes has not been determined.
Chickens have many differences in their lipid, glucose, and glycogen metabolism as well as differences in the regulation of hormones compared with mammals (35) . Studies on the metabolism in chicken hepatocytes compared with those of mammals are quite interesting. A primary culture of hepatocytes has been used for many biophysiological studies on liver function because a primary culture of hepatocytes retains many of the liver-specific functions and responds to various hormones by the expression of liver-specific functions. The primary chicken hepatocytes culture system utilized in this study has also been recognized to retain in vitro the differentiated phenotype typical of the liver, including albumin expression (17) , cytochrome P-450 1A induction (17) , tyrosine aminotransferase expression (39) , and ascorbate recycling (40) . Moreover, chickens are characterized by a blood glucose level that is twice as high as that in most mammals (1) . The cellular glucose level is modulated by facilitative GLUTs. Among the many isoforms of the GLUT family, GLUT2 is expressed predominantly in the liver of chickens and mammals, which can be regulated by phloretin (25, 48) and can play a crucial role in chicken whole body glucose homeostasis. Therefore, this study examined the effect of EGF on GLUT2 activity and its related signaling pathways in primary cultured chicken hepatocytes.
MATERIALS AND METHODS
Materials. Two-week-old white Leghorn male chickens were obtained from Dae Han Experimental Animal (Chungju, Korea). All the procedures for animal management followed the standard operation protocols of Seoul National University. The appropriate management of experimental samples and quality control of the laboratory facility and equipment were maintained. The class IV collagenase and soybean trypsin inhibitors were purchased from Life Technologies (Grand Island, NY). Fetal bovine serum was purchased from Biowhittaker (Walkersville, MD). EGF, AG-1478, herbimycin A, genistein, PD-98059, SB-203580, and SP-600125 were obtained from Sigma Chemical (St. Louis, MO). Phospho-p44/42 MAPKs, p44/42 MAPKs, phospho-p38 MAPK, and p38 MAPK antibodies were purchased from New England Biolabs (Herts, UK). The antibodies to total EGFR, phospho-EGFR, SAPK/JNK, and GLUT2 were obtained from Santa Cruz Biotechnology (Santa Cruz, CA). The liquiscint was obtained from National Diagnostics (Parsippany, NY, USA). Goat anti-rabbit IgG was purchased from Jackson Immunoresearch (West Grove, PA). All other reagents were of the highest purity commercially available.
Primary culture of chicken hepatocytes. Chicken liver cells were prepared and maintained in a monolayer culture as described previously (12) . Briefly, chicken hepatocytes were isolated by perfusion with 0.05% collagenase from a liver that had been starved for 3 h. Hepatocytes with Ͼ90% viability, as verified by a trypan blue exclusion test, were used for subsequent plating. Hepatocytes were plated (5.0 ϫ 10 5 cells/60-mm collagen-coated dish) with incubation medium (basal medium Eagle supplemented with essential amino acids) containing 75 U/ml penicillin, 75 U/ml streptomycin, 1 g/ml insulin, 10 Ϫ12 M dexamethasone, 5 g/ml transferrin, 10 Ϫ8 M thyroxine (T3), and 5% calf serum and incubated for 4 h at 37°C in 5% CO2. The medium was subsequently replaced with fresh incubation medium, and hepatocytes were incubated for a further 20 h to achieve the monolayer culture. The experiments were then carried out.
Uptake experiments. The 2-[ 3 H]deoxyglucose (2-DG) uptake experiments were carried out using a modification of the method described by Henriksen et al. (20) . To study the 2-DG uptake, the culture medium was removed by aspiration, and cells were gently washed twice with uptake buffer (140 mM NaCl, 2 mM KCl, 1 mM KH2PO4, 10 mM MgCl2, 1 mM CaCl2, 5 mM glucose, 5 mM L-alanine, 5 M indomethacin, and 10 mM HEPES-Tris; pH 7.4). After being washed, cells were incubated in uptake buffer containing 1 Ci/ml 2-DG at 37°C for 30 min. At the end of the incubation period, cells were washed three times with ice-cold uptake buffer and dissolved in 1 ml of 0.1% SDS. The level of 2-DG uptake incorporated intracellulary was determined by removing 900 l of each sample and measuring the radioactivity in a liquid scintillation counter (LS 6500, Beckman Instruments, Fullerton, CA). The remainder of each sample was used to determine the protein level (2). The radioactivity counts in each sample were then normalized with respect to the protein and corrected for time 0 uptake per milligram of protein.
All uptake measurements were carried out in triplicate.
Membrane preparation for Western blot analysis. The medium was then removed, and cells were washed twice with ice-cold PBS, scraped, harvested by microcentrifugation, and resuspended in buffer A (137 mM NaCl, 8.1 mM Na2HPO4, 2.7 mM KCl, 1.5 mM KH2PO4, 2.5 mM EDTA, 1 mM dithiothreitol, 0.1 mM PMSF, and 10 g/ml leupeptin; pH 7.5). The resuspended cells were lysed mechanically on ice by trituration with a 21.1-gauge needle. Lysates were first centrifuged at 1,000 g for 10 min at 4°C. Supernatants were centrifuged at 100,000 g for 1 h at 4°C to prepare the cytosolic and total particulate fractions. The particulate fractions containing the membrane fraction were washed twice and resuspended in buffer A containing 1% Triton X-100. The protein level in each fraction was quantified using the Bradford procedure (2) .
RNA isolation and RT-PCR. Total RNA was extracted from the cells using STAT-60, which is a monophasic solution of phenol and guanidine isothiocyanate purchased from Tel-Test (Friendwood, TX). RT was carried out with 3 g RNA using a RT system kit (AccuPower RT PreMix) with oligo-dT18 primers. Five microliters of RT products were then amplified with a PCR kit (AccuPower PCR PreMix) using the following procedure: denaturation at 94°C for 5 min and 30 cycles at 94°C for 30 s, 55°C for 30 s, and 72°C for 1 min, followed by a 5-min extension at 72°C. The primers used were as follows: 5Ј-TGTTCAGCTCCTCCAAGTACC-3Ј (sense) and 5Ј-ACAACGAACACATACGGTCC-3Ј (antisense) for GLUT2 (523 bp). PCR of ␤-actin was also performed as a control to confirm the quantity of RNA. RT-PCR products were separated and visualized on 1.2% agarose gels. PCR products were analyzed by calculating the quantitative values of the EGF treatment group relative to the control group and standardizing the data relative to ␤-actin.
Western blot analysis. Cell homogenates (20 g protein) were separated by 10% SDS-PAGE and transferred to nitrocellulose paper. Blots were then washed with H2O, blocked with 5% skim milk powder in Tris-buffered saline-Tween 20 [10 mM Tris ⅐ HCl (pH 7.6), 150 mM NaCl, and 0.05% Tween-20] for 2 h, and incubated with the primary polyclonal antibody at the dilutions recommended by the supplier. The membrane was then washed, and the primary antibodies were detected with goat anti-rabbit IgG conjugated to horseradish peroxidase. Bands were visualized using enhanced chemiluminescence (Amersham Pharmacia Biotech).
Statistical analysis. Results are expressed as means Ϯ SE. All experiments were analyzed by ANOVA. In some experiments, a comparison of the treatment means was made with the control using the Bonnferroni-Dunn test. A P value of Ͻ0.05 was considered significant.
RESULTS

Time-and dose-dependent effects of EGF on 2-DG uptake.
The time-dependent effect of EGF on 2-DG uptake was determined by exposing chicken hepatocytes to 100 ng/ml EGF for various times (0 -24 h). EGF significantly inhibited 2-DG uptake over a 2-h period and exhibited the maximum inhibitory effect between 8 and 12 h (Fig. 1A) . There was no significant difference between 8 and 24 h. The dose-dependent effect of EGF on 2-DG uptake was also determined (Fig. 1B) . Therefore, chicken hepatocytes were exposed to various concentrations of EGF for 8 h. EGF (Ն10 ng/ml) significantly inhibited 2-DG uptake. The maximum effect was observed between 100 ng/ml and 1 g/ml EGF. Therefore, the following experiments used 100 ng/ml EGF for 8 h. GLUT2 gene and protein expression levels were downregulated in response to EGF (Fig. 1C) .
Receptor and tyrosine kinase dependency of EGF on 2-DG uptake. To determine whether the effect of EGF was dependent on EGFR, chicken hepatocytes were treated with AG-1478 (10 Ϫ5 M) before the EGF treatment. As shown in Fig. 2B , there was no inhibitory effect of EGF. The EGF-induced inhibition of 2-DG uptake was also blocked by either herbimycin A or genistein (10 Ϫ6 M) (tyrosine kinase inhibitors; Fig. 2A ). Indeed, EGF increased phosphorylation of EGFR over 5 min, and its effect was sustained for 8 h (Fig. 2B) . These results suggest that the inhibitory effect of EGF on 2-DG uptake requires the activation of the EGFR with the tyrosine kinase residue.
Involvement of PKC in the EGF-induced decrease of 2-DG uptake. The relationship between PKC in the EGF-induced decrease in 2-DG uptake was examined. Staurosporine, H-7, or bisindolylmaleimide I (PKC blockers, 10 Ϫ7 M) blocked the EGF-induced decrease in 2-DG uptake (Fig. 3A) . To certify this result, PKC translocation was examined using the pan-PKC antibody. Indeed, the translocation of PKC from the cytosolic to membrane compartment was observed after an 8-h treatment with 100 ng/ml EGF (Fig. 3B) . The Western blot analysis of PKC isoforms revealed that PKC-␣, -␤ 1 , -␥, -␦, and -were translocated from the cytosolic to membrane compart-ment, suggesting a role of these isoforms in the effect of EGF. The correlation between the EGF-induced decrease in 2-DG uptake and the GLUT2 expression level was examined. Figure 4 shows the EGF-induced decrease of the GLUT2 expression level, which was blocked by AG-1478, herbimycin, staurosporine, and bisindolylmaleimide I, thus supporting the role of PKC.
Involvement of MAPKs in the EGF-induced decrease of 2-DG uptake.
To determine whether MAPKs are involved in the EGF-induced decrease in 2-DG uptake, chicken hepatocytes were treated with PD-98059 (MEK inhibitor), SB-203580 (p38 MAPK inhibitor), or SP-600125 (SAPK/JNK inhibitor) for 30 min before the EGF treatment. Figure 5A shows that SB-203580, PD-98059, and SP-600125 significantly prevented the EGF-induced decrease in 2-DG uptake (P Ͻ 0.05). In addition, EGF enhanced phosphorylation of p44/42 MAPKs, p38 MAPK, and JNK. Maximal peaks appeared at 10 min for p44/42 MAPKs, 30 min for p38 MAPK, and 30 min for JNK after EGF treatment, respectively (Fig.  5B) . Total protein levels of these MAPKs by Western blot analysis were similar. As shown in Fig. 5C , AG-1478, herbimycin A, or bisindolylmaleimide I blocked the EGF-induced phosphorylation of p44/42 MAPKs, p38 MAPK, and JNK. This suggests that all the MAPK pathways including p44/42 MAPKs, p38 MAPK, and SAPK/JNK are involved in the EGF-induced decrease in 2-DG uptake. Figure 6 shows that EGF decreased the expression of GLUT2. This effect was blocked by SB-203580, PD-98059, and SP-600125, which supports the role of all MAPKs.
DISCUSSION
GLUTs are regulated by various factors including mitogens, oncogenes, cytokines, and growth factors. This study examined the EGF signal transduction pathway that mediates the alteration in GLUT activity in primary cultured chicken hepatocytes. Several lines of evidence have suggested that EGF affects GLUTs in a short time period in various cells (16, 46) . However, in the present study, EGF did not affect glucose 3 H]deoxyglucose (2-DG) uptake. Chicken hepatocytes were treated with EGF (100 ng/ml) for different times (0 -24 h) or doses of EGF (1-1,000 ng/ml) before the uptake experiments. Values are represented as means Ϯ SE of 3 independent experiments with triplicate dishes. C, top: glucose transporter 2 (GLUT2) gene (left) and protein (right) expression levels were determined by RT-PCR and Western blot analysis, respectively. Hepatocytes were treated with EGF (100 ng/ml) for 8 h. Genes were 523 bp for GLUT2 and 350 bp for ␤-actin. Membrane protein blots were probed with GLUT2-or ␤-actin-specific antibodies. Bands represent 50ϳ60 kDa of GLUT2 and 41 kDa of ␤-actin, respectively. C, bottom: bars indicating means Ϯ SE of 3 experiments for each condition determined from densitometry relative to ␤-actin. *P Ͻ 0.05 vs. control (Con). transport over a short time (Ͻ1 h). Unexpectedly, it was found that EGF caused a time-dependent (Ͼ2 h) and dose-dependent decrease in GLUT activity. These inhibitory effects of GLUT activity were mediated by the long-term action of EGF via the decrease of mRNA/protein levels in GLUT2, which is the major isoform in chicken hepatocytes (25) . We also observed that EGF downregulated GLUT1 expression, which contributed to the inhibitory effect of GLUTs (data not shown). In conflict with these results, EGF stimulates GLUT activity in enterocytes (8) . This discrepancy may be due to the difference in species (chickens vs. rabbits) or cell specificity (hepatocytes vs. enterocytes). Avian GLUTs are regulated via different mechanisms from those in mammals. The control of GLUTs by the v-src oncogene in chicken embryo fibroblasts appears to be different from that in rat embryo fibroblasts (49) . Moreover, the expression levels of high-affinity GLUT isoforms are ubiquitous in all chicken tissues compared with mammals. This difference can explain the different functional role of GLUT1 and GLUT3 in chickens compared with mammals (47) . Although the physiological levels of EGF were defined at 3-10 ng/ml, high EGF concentrations (100, 500, and 1,000 ng/ml) have been used under various experimental conditions and different cell types (5, 36) . In this study, the decrease in effective 2-DG uptake appeared at a wide range of EGF concentrations (10, 100, and 1,000 ng/ml). These variations may be due to difference in cell types, marker indexes, or experimental conditions. EGF signaling is initiated by binding to its receptor. This receptor is activated by autophosphorylation, after which it interacts with a variety of proteins in the signal transduction pathway leading to the inhibition of GLUTs. Hardy et al. (13) reported similar results in that the signaling domains in the carboxy terminus of the EGFR are essential for this receptor to induce glucose transport. This study found that the EGFRinduced decrease in glucose transport requires a phosphotyrosine motif in the EGFR because an EGFR antagonist and tyrosine kinase inhibitors blocked the EGF-induced decrease in glucose transport. This result is also supported by a report showing that hepatocytes have an EGFR with a tyrosine phosphorylation residue (28, 42) .
EGF-stimulated tyrosine kinase activity has been shown to activate phospholipase C (PLC)-␥ (22, 32) . Once activated, this enzyme catalyzes the hydrolysis of phosphatidylinositol in the plasma membrane into diacylglycerol (DAG) and Ins(1,4,5)P 3 . Signal transduction within the cell then continues down two pathways. DAG activates PKC, and Ins(1,4,5)P 3 releases Ca 2ϩ from intracellular stores to increase the Ca 2ϩ concentration. In accordance with these reports, EGF was found to activate the PKC family downstream of the signaling by PLC, and PKC activation is involved in the EGF-induced decrease in 2-DG uptake. These effects of EGF are restricted to chicken hepatocytes but not to rat hepatocytes, because EGF Fig. 3 . Effect of PKC inhibitors on EGF-induced 2-DG uptake and effect of EGF on PKC activation. A: chicken hepatocytes were treated with staurosporine, H-7, or bisindolylmaleimide I (10 Ϫ7 M) for 30 min before EGF treatment (100 ng/ml) for 8 h. Values are represented as means Ϯ SE of 3 independent experiments with triplicate dishes. *P Ͻ 0.05 vs. control; **P Ͻ 0.05 vs. EGF alone. B: PKC protein levels, which were present in either the cytosolic and membrane fractions, were then detected using Western blot analysis as described in MATERIALS AND METH-ODS. The arrow indicates the 82-kDa band corresponding to PKC. ␤-Actin was used as a control. C: effect of EGF on the expression of PKC isoforms. PKC-␣, -␤1, -␥, -␦, and -were detected in response to EGF. did not stimulate DAG synthesis and the EGF-induced mitogenic effect is PKC independent in rat hepatocytes (4) . In the present study, we identified that PKC-␣, -␤ 1 , -␥, -␦, and -are translocated from the cytosolic to membrane fraction in response to EGF in chicken hepatocytes. However, Marino et al. (27) reported that EGF translocated only PKC-␣ and -⑀ among the PKC isoforms from the cytosolic to membrane fraction in chicken embryo hepatocytes. The discrepancy may be due to the difference of developmental stage (postnatal vs. prenatal).
Three principal MAPKs were expressed in hepatocytes: p44/42 MAPKs, JNK, and p38 MAPK (30, 45) . In this study, EGF increased three MAPKs in a time-dependent manner in chicken hepatocytes. It was interesting that in this study, unlike in other reports, p44/42 MAPKs and JNK have one band instead of two. The reason for this is unclear but may be due to the specificity of species. Surprisingly, all the inhibitors of the three MAPKs blocked the EGF-induced decrease in glucose uptake and GLUT2 expression. These results are in agreement with those of a study in rat hepatocytes in which the effect of EGF was inhibited completely by PD-98059 and partially by SB-203580 (30) . A recent report has also revealed the involvement of p38 MAPK in the downregulation of GLUT4 expression (3). Furthermore, this study provided other evidence that SAPK/JNK also is involved in the effect of the EGF-induced decrease in glucose transport. Although the signal pathways between the three MAPKs are different, there may be crosstalk between the three MAPKs. A recent report also demonstrated cross-talk between the MAPKs (41). Of interest is that EGF-induced activation of these MAPKs is involved in the transcriptional regulation of GLUT2. A recent report has suggested that the chronic activation of p38 MAPK, p44/42 MAPKs, and p38 MAPK can induce the alteration of GLUT mRNA levels (7) . Other investigators have also demonstrated that the activation of p44/42 MAPKs, p38 MAPK, or JNK is involved in the effect of GLUT1 mRNA levels in various cells (38, 52) . Although these reports did not reveal direct evidence, they support our hypothesis that EGF can decrease the level of GLUT2 mRNA via activation of three MAPKs.
The relative importance of PKC in the activation of the p44/42 MAPK pathway has been shown to depend on the Ϫ6 M) for 30 min before EGF treatment (100 ng/ml). B: chicken hepatocytes were treated with EGF (100 ng/ml) for different time points (0 -90 min). Phosphorylation of p44/42 MAPKs, p38 MAPK, and JNK were detected as described in MATERIALS AND METHODS. C: chicken hepatocytes were treated with AG-1478, herbimycin A, or bisindolymaleimide I for 30 min before EGF treatment (100 ng/ml), and the phosphorylation of p44/42 MAPKs, p38 MAPK, and JNK was then detected. Each example shown is a representative of 3 experiments. Values are represented as means Ϯ SE of 3 independent experiments with triplicate dishes. *P Ͻ 0.05 vs. control; **P Ͻ 0.05 vs. EGF alone. agonist and cell types (37, 44) . In hepatocytes, PKC-dependent activation of p44/42 MAPKs is involved in ischemic preconditioning (8) . Moreover, there is some controversy regarding the role of PKC in the EGF stimulation of the p44/42 MAPK pathway (11, 33) . This study demonstrated that PKC plays a role in the EGF-induced activation of p44/42 MAPKs. In addition, evidence was provided to show that PKC activation is also responsible for the EGF-induced stimulation of p38 MAPK and JNK. To our knowledge, this is the first report of a new mechanism showing that EGF induced the phosphorylation of EGFR and caused the activation of PKC, thereby leading the activation of three MAPKs (p38 MAPK, p44/42 MAPKs, and JNK) that are involved in the inhibition of GLUTs in chicken hepatocytes. These results can provide a better understanding of the regulation of EGF in GLUTs and the involvement of various signaling molecules in chicken hepatocytes. In conclusion, EGF inhibited GLUT activity via the PKC-MAPK signal cascade in primary cultured chicken hepatocytes. 
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